The AAPS Journal

, 21:1 | Cite as

Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir

  • Elodie Valade
  • Thomas N. Kakuda
  • Matthew W. McClure
  • Christopher Westland
  • Belén Valenzuela
  • Sivi Ouwerkerk-Mahadevan
  • Juan José Perez-Ruixo
  • Oliver AckaertEmail author
Research Article Theme: Pioneering Pharmaceutical Science by Emerging Investigators
Part of the following topical collections:
  1. Theme: Pioneering Pharmaceutical Science by Emerging Investigators


The aim of the current study was to characterize the time course of plasma concentrations of AL-335 and its main metabolites (ALS-022399 and ALS-022227) after oral administration in healthy and hepatitis C virus (HCV)-infected subjects, in monotherapy as well as in combination with simeprevir and/or odalasvir. AL-335, ALS-022399, and ALS-022227 plasma concentrations from subjects receiving 800 mg of AL-335 orally once daily (qd) as monotherapy or in combination were pooled and analyzed using a nonlinear mixed effect modeling approach. The typical values (between subject variability) of AL-335 and ALS-022399 apparent linear clearances were 3300 L/h (33.9%) and 1910 L/h (30.0%), respectively. ALS-022227 elimination was characterized as a nonlinear process, with typical values of Vmax,ALS-022227 and Km,ALS-022227 estimated to be 84,799 ng/h (14.9%) and 450.2 ng/mL, respectively. AL-335 and ALS-022399 plasma concentrations were increased more than 2-fold in presence of simeprevir and/or odalasvir, while the effect on ALS-022227 plasma concentrations was limited. The effect of simeprevir and/or odalasvir might be explained by their capacity to inhibit P-glycoprotein. Internal evaluation confirmed that the population pharmacokinetic model developed was deemed appropriate to describe the time course of AL-335, ALS-022399, and ALS-022227 plasma concentrations and their associated variability in both healthy and HCV-infected subjects, as well as the interaction effect of simeprevir and/or odalasvir over AL-335 and its metabolites in healthy subjects. This model can be used as a starting point to evaluate drug-drug interaction processes in HCV-infected patients and support the development of a direct-acting antiviral (DAA) combination.


direct-acting antiviral (DAA) drugs hepatitis C virus (HCV) nonlinear mixed effects modeling pharmacokinetics uridine nucleoside analog 



The authors thank Eef Hoeben for her comments and support during the analysis. In addition, the authors would like to thank the patients, investigators, and their medical, nursing, and laboratory staff who participated in the clinical trials included in the present study.

Compliance with Ethical Standards

Each protocol was reviewed and approved by an institutional review board and written informed consent was obtained from each subject before enrollment in the studies, after being advised of the potential risks and benefits of the study. The studies were conducted in agreement with the Declaration of Helsinki, Good Clinical Practices guidelines, and other applicable regulatory requirements.

Conflict of Interest

Matthew W. McClure was an employee of Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies, at the time this study was conducted.


  1. 1.
    World Health Organization. Fact sheet hepatitis C. July 2017. Accessed 26 Sep 2017.
  2. 2.
    Pawlotsky J-M, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology. 2007;132(5):1979–98. Scholar
  3. 3.
    World Health Organization. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version April 2016. 2016. Accessed 18 Sep 2017.
  4. 4.
    Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology. 2016;64(2):360–9. Scholar
  5. 5.
    Lawitz E, Poordad F, Hyland RH, Wang J, Liu L, Dvory-Sobol H, et al. Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two phase II studies. Antivir Ther. 2016;21(8):679–87. Scholar
  6. 6.
    National Center for Biotechnology Information. PubChem Compound Database; CID=118596336, Accessed 16 Aug 2018.
  7. 7.
    Tan H, Shaw K, Jekel A, Deval J, Jin Z, Fung A, et al. Preclinical characterization of AL-335, a potent uridine based nucleoside polymerase inhibitor for the treatment of chronic hepatitis C. J Hepatol. 2015;62(2):S577–8.CrossRefGoogle Scholar
  8. 8.
    Gerber L, Welzel TM, Zeuzem S. New therapeutic strategies in HCV: polymerase inhibitors. Liver Int. 2013;33(1):85–92. Scholar
  9. 9.
    OLYSIO® (simeprevir) prescribing-information. 2013. Accessed 18 Sep 2017.
  10. 10.
    Kakuda TN, McClure MW, Westland C, Vuong J, Homery M-C, Poizat G, et al. Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects. Pharmacol Res Perspect. 2018;60(3):e00395. CrossRefGoogle Scholar
  11. 11.
    Ouwerkerk-Mahadevan S, Snoeys J, Peeters M, Beumont-Mauviel M, Simion A. Drug-drug interactions with the NS3/4A protease inhibitor simeprevir. Clin Pharmacokinet. 2016;55(2):197–208. Scholar
  12. 12.
    Beal S, Boeckman A, Scheiner L. NONMEM user’s guides. San Francisco,CA: University of California at San Francisco. 1988.Google Scholar
  13. 13.
    R Development Core Team 2007. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL
  14. 14.
    Bertrand J, Laffont CM, Mentré F, Chenel M, Comets E. Development of a complex parent-metabolite joint population pharmacokinetic model. AAPS J. 2011;13(3):390–404. Scholar
  15. 15.
    Valade E, Hoeben E, Kakuda TN, McClure M, Westland C, Perez Ruixo J, Ackaert O. Population pharmacokinetic modeling of simeprevir – odalasvir interaction in healthy volunteers. 26th Population Approach Group in Europe, June 2017; Budapest, Hungary. Accessed 26 Sep 2017.
  16. 16.
    Brendel K, Comets E, Laffont C, Laveille C, Mentré F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23(9):2036–49. Scholar
  17. 17.
    Nguyen TH, Comets E, Mentré F. Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model. J Pharmacokinet Pharmacodyn. 2012;39(5):499–518. Scholar
  18. 18.
    Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001;28(2):171–92.CrossRefGoogle Scholar
  19. 19.
    Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008;35(4):401–21. Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  • Elodie Valade
    • 1
  • Thomas N. Kakuda
    • 2
  • Matthew W. McClure
    • 2
  • Christopher Westland
    • 2
  • Belén Valenzuela
    • 3
  • Sivi Ouwerkerk-Mahadevan
    • 1
  • Juan José Perez-Ruixo
    • 1
  • Oliver Ackaert
    • 1
    Email author
  1. 1.Janssen Research and Development, Global Clinical PharmacologyBeerseBelgium
  2. 2.Alios BioPharma, Inc., part of the Janssen Pharmaceutical CompaniesSouth San FranciscoUSA
  3. 3.SGS Exprimo NVMechelenBelgium

Personalised recommendations